Aclaris Therapeutics, Inc. (ACRS)
- Previous Close
1.2200 - Open
1.2100 - Bid 1.1400 x 100
- Ask 1.1900 x 400
- Day's Range
1.1400 - 1.2350 - 52 Week Range
0.5900 - 11.1200 - Volume
1,308,835 - Avg. Volume
1,074,790 - Market Cap (intraday)
86.529M - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2200 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.80
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
www.aclaristx.com86
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ACRS
Performance Overview: ACRS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACRS
Valuation Measures
Market Cap
86.53M
Enterprise Value
-32.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.73
Price/Book (mrq)
0.55
Enterprise Value/Revenue
-1.03
Enterprise Value/EBITDA
0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
-283.15%
Return on Assets (ttm)
-32.53%
Return on Equity (ttm)
-49.88%
Revenue (ttm)
31.25M
Net Income Avi to Common (ttm)
-88.48M
Diluted EPS (ttm)
-1.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
119.11M
Total Debt/Equity (mrq)
2.23%
Levered Free Cash Flow (ttm)
-39.92M